Eli Lilly and Company & GSK plc

Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.

GSK plc: GSK plc has adopted a more aggressive M&A approach following recent CEO transitions, contributing to the overall increase in dealmaking.

Eli Lilly and Company: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.

GSK plc: GSK plc>>>'s drug Avodart is mentioned in a comparison study where GLP-1s were associated with lower rates of prostate cancer diagnoses.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

GSK plc: GSK plc's shares rose after it agreed to acquire GSK plc for $10.6 billion, indicating positive market reception to its strategic acquisition.

GSK plc: GSK plc is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.